Kiora Pharmaceuticals Inc. (KPRX) Price-to-Projected Revenue Ratio

Corporate company logo of Kiora Pharmaceuticals, Inc. (KPRX)

Kiora Pharmaceuticals (KPRX) is attracting leading ophthalmologists to develop treatments for rare eye pathologies. The expected P/S dynamics on GURU.Markets confirm this status, with the parameter reaching 5.50. While the current revenue deficit and capital burn result in negative earnings, the strategy to scale retina testing is aimed at securing commercial B2B partnerships as quickly as possible.

KPRX Kiora Pharmaceuticals, Inc.: Forward Price to Sales in the range 05/12/2024 - 11/14/2026

Comprehensive metric breakdowns and analytics for kiorapharma.com (KPRX)

- current price and projected stock value:
Stock Price Kiora Pharmaceuticals, Inc.|KPRX - Analyst Median Target
- market capitalization details:
Market Value Kiora Pharmaceuticals|KPRX - Total Enterprise Value
- book value of equity indicators:
Net Assets per Single Share Kiora Pharmaceuticals|KPRX - Accounting Value of Company|Market Capitalization to Book Value Ratio kiorapharma.com|KPRX - Company Total Assets
- debt and liquidity data:
Total Debt to Equity Ratio Kiora Pharmaceuticals|KPRX - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Kiora Pharmaceuticals, Inc.|KPRX - Company Aggregate Indebtedness|Debts to Book Capitalization Kiora Pharmaceuticals|KPRX - Company Long-Term Loans and Borrowings|Company Short-Term Debts Kiora Pharmaceuticals|Quick Liquidity kiorapharma.com
- business earnings and investment ratios data:
KPRX - Final Profit|Expected Profit Kiora Pharmaceuticals|KPRX - Price to Earnings Ratio|Forward P/E Multiple Kiora Pharmaceuticals, Inc.|KPRX - PEG Multiple|EV/EBITDA Multiple Kiora Pharmaceuticals|KPRX - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Kiora Pharmaceuticals|KPRX - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months kiorapharma.com|KPRX - Earnings growth in current year|Expected earnings per share growth for next year Kiora Pharmaceuticals
- company sales and revenue statistics:
KPRX - Company Total Sales|Projected Sales Volume Kiora Pharmaceuticals, Inc.|KPRX - Price-to-Revenue Coefficient|Forward P/S Multiple Kiora Pharmaceuticals
Fundamental valuation:Kiora Pharma KPRX
Manufactured products of Kiora Pharmaceuticals, Inc.

The forward P/S ratio compares the current market value of Kiora Pharmaceuticals (KPRX) with expected future sales volume, allowing for an assessment of capitalization efficiency relative to prospective cash flows. Analyzing the company's forward P/S helps determine the asset's margin of safety, which is particularly relevant for the non-cyclical ophthalmology sector, where business value depends on the success of clinical trials and patent protection rather than macroeconomics.

Key competitors

Forward P/S Multiple ALC (Alcon)|Market Cap to Expected Sales Ratio Bausch & Lomb (BLCO)|GKOS - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Apellis Corp|belitebio.com (BLTE) - Price-to-Projected Revenue Ratio|ocutx.com - Forward Price to Sales|HROW (Harrow) - Forward P/S Multiple|Forward P/S Multiple Viridian Therapeutics Inc|Forward Price-to-Revenue Multiple LENZ (LENZ Pharma)|OCS (Oculis Pharma) - Forward Price to Sales|Price-to-Projected Revenue Ratio EyePoint Pharmaceuticals EYPT|KOD (kodiak.com) - Future Price to Revenue|Aldeyra - Forward P/S Multiple|Forward Price to Sales KALA (KALA BIO, Inc.)|IRD: Forward P/S Multiple|OKYO Pharma (OKYO) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Adverum Biotechnologies Inc.|OTLK: Forward Price to Sales|Price-to-Projected Revenue Ratio Clearside Biomedical, Inc. (CLSD)|Forward Price-to-Revenue Multiple novabay.com NBY|Forward P/S Multiple ALIM (Alimera Sciences, Inc.)|Forward P/S Multiple Eyenovia Inc. EYEN|Guardion Health Science - Forward P/S Multiple|ocuphire.com (OCUP) - Forward Price-to-Revenue Multiple|OPT: Forward P/S Multiple